Previous studies have reported dysregulated TSPO expression across various malignancies, including breast cancer (33–35), head and neck squamous cell carcinoma (36), and oral squamous cell carcinoma (37, 38), where its expression levels correlate with tumor aggressiveness and patient prognosis. Here, TSPO is linked to breast cancer.